Chemical structure of abacavir.
Find information on thousands of medical conditions and prescription drugs.

Abacavir

Abacavir (ABC) is the most powerful nucleoside analog reverse transcriptase inhibitor (NARTI) used to treat HIV and AIDS. It has been well tolerated, its main side effect being hypersensitivity reactions, which can be dangerous. It is available under the trade name Ziagen™ by GlaxoSmithKline and the combination drug Trizivir™. more...

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Abacavir is one of the most deadly NARTIs, due its ability to trigger to hypersensitivity reactions that lead to sudden death in certain individuals. However, a genetic test is now available that, while not perfect, has reasonable accuracy in predicting whether an individual will be hypersensitive. Over 90% of patients can safely take abacavir.

Strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally sensitive to abacavir, whereas strains that are resistant to AZT and 3TC are not as sensitive to abacavir.

History

Abacavir was approved by the Food and Drug Administration (FDA) on December 18, 1998 and is thus the fifteenth approved antiretroviral drug in the United States. Its patent will expire in the United States on 2009-12-26.

Mechanism of action

ABC is an analog of guanosine. It is capable of crossing the blood-brain barrier.

Abacavir is given orally and has a high bio-availability of 83%. It is metabolised primarily through alcohol dehydrogenase or gluconyl transferase.

Read more at Wikipedia.org


[List your site here Free!]


ABACAVIR - Ziagen
From Research Initiative/Treatment Action!, 3/1/00

Abacavir tablets are yellow, capsule-shaped, film-coated and imprinted with "GX623" on one side. The drug is also available in an oral solution.

"Approval of abacavir will offer patients another 'choice' in antiretroviral therapy, but data so far suggest that the choice is not a functionally important one; rather, it's more like the choice between a blue pill and a red one."

Tagline, 1998

"Newly approved abacavir ... promises to be one of the most potent antiretroviral agents available for treatment of HIV infection."

Treatment Issues, 1999

Also known as: ABV, 1592, abacavir sulfate

Background and description. Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI). This drug is the most powerful in its class and one of the most potent antiretrovirals available. The US Food and Drug Administration (FDA) approved abacavir in December 1998. The drug is manufactured by Glaxo Wellcome. Abacavir is indicated in combination with other antiretrovirals for the treatment of HIV infection.

Guidelines classification. The Panel on Clinical Practices for the Treatment of HIV Infection classifies abacavir as an "alternative" NRTI.

Dose. The recommended dose of abacavir for adults is 300 mg (1 tablet) twice a day.

Food restrictions. Abacavir may be taken with or without food.

Storage. The tablets should be stored at a room temperature of 68 [degrees] to 77 [degrees] F; the solution should be kept at room temperature or refrigerated, but not frozen.

Side effects and toxicity. The side effects most commonly associated with abacavir therapy include nausea, vomiting, fatigue, headache, diarrhea and loss of appetite. As a class, NRTIs have been implicated in damage to mitochondrial DNA and may therefore play a role in the development of metabolic and morphologic abnormalities. The most serious side effect, however, is a hypersensitivity reaction that occurs in approximately 5% of those receiving abacavir. Symptoms of abacavir hypersensitivity usually appear within the first 6 weeks of treatment and include a skin rash or 2 or more of the following sets of symptoms: fever, nausea, vomiting, diarrhea or abdominal pain, severe tiredness, achiness or a general sense of ill-health. A recent review of cases revealed that respiratory symptoms including cough, dyspnea (shortness of breath), and pharyngitis (sore throat) occurred in approximately 20% of patients having hypersensitivity reactions. Deaths have been reported in patients receiving abacavir who were initially diagnosed with an acute respiratory disease, but were later recognized to have had hypersensitivity reactions. Patients who believe they are experiencing abacavir hypersensitivity should stop taking the drug and call their physician immediately. Those who experience hypersensitivity to abacavir must never take the drug again. Any effort to rechallenge can produce life-threatening symptoms.

Drug interactions. Abacavir is not known to have clinically significant interactions with other drugs.

Resistance and cross-resistance. Patients who have used and developed resistance to multiple NRTIs are unlikely to reduce their viral load with the use of abacavir. On the other hand, patients who have used and developed resistance to only two NRTIs may see significant reductions in viral load when abacavir is combined with other drugs. In a Glaxo Wellcome-sponsored expanded access program, which provided the drug to patients with advanced disease and few treatment options, abacavir produced a 0.5 log reduction in viral load for only 1 in 4 patients.

Clinical data. In a pivotal study of abacavir, a team of Glaxo Wellcome investigators randomized 86 patients to a regimen of zidovudine (Retrovir)/lamivudine (Epivir) and another 87 to a combination of abacavir/ zidovudine/lamivudine. Participants were required to be naive to antiretroviral therapy. The median baseline viral load among the study subjects was approximately 38,000 copies/mL, while the median baseline CD4 T cell count was approximately 450 cells/[mm.sup.3]. At the end of the first 16 weeks, which were double-blind, approximately 80% of the subjects in the 3-drug arm had undetectable viral loads (less than 400 copies/mL). Unsurprisingly, less than 40% of the subjects in the double-NRTI comparison arm had undetectable plasma viremia. By week 48, approximately 60% of the triple-therapy subjects still had undetectable viral loads; however, participants with a baseline viral load of greater than 100,000 copies/mL were much less likely than other subjects to achieve undetectable viremia with the use of abacavir. Glaxo Wellcome reports that only 6% of the subjects assigned to the 3-drug group withdrew from study for adverse events.

For those who have been heavily treated with other NRTIs, abacavir may have limited utility because of pre-existing resistance. However, for patients with limited or no NRTI experience, this nucleoside offers a potent, convenient and generally well-tolerated choice.

Patient assistance. Glaxo Wellcome provides a patient assistance program. For more information, call 800.722.9294.

COPYRIGHT 2000 The Center for AIDS: Hope & Remembrance Project
COPYRIGHT 2000 Gale Group

Return to Abacavir
Home Contact Resources Exchange Links ebay